Ginkgo Bioworks and the Rwanda Biomedical Centre announced a one-year pathogen monitoring program at Rwanda’s Kigali International Airport to identify new and emerging variants of SARS-CoV-2. Through this program, Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, will collaborate with RBC to monitor wastewater samples from arriving aircraft and nasal swab samples, collected on a voluntary, anonymous basis from arriving international travelers, for SARS-CoV-2. The program aims to provide critical public health insights to help inform mitigation strategies in Rwanda and globally. The program builds on Ginkgo’s previously announced MOU to develop and implement biosecurity capabilities in Rwanda. Ginkgo will support the end-to-end collection and analysis workflow with materials, training and logistical support, digital platform and data reporting, as well as bioinformatics and decision support services.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DNA:
- Cathie Wood Gets Back on Track; Here Are 2 Stocks She’s Snapping Up
- Ginkgo Bioworks and NAMUH announce collaboration to develop HMOs
- Ginkgo Bioworks, Xwell expand support for CDC’s Genomic Surveillance program
- Ginkgo Bioworks and Xwell partner in influenza variant detection for CDC
- Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review